FDA Issues Guidance On Off-Label Info; Waxman Seeks ‘Re-examination’
This article was originally published in The Gray Sheet
Executive Summary
Rep. Henry Waxman is calling for the Obama administration to re-examine a final FDA guidance that gives companies a way to distribute journal articles discussing off-label uses for approved medical devices and drugs
You may also be interested in...
Off-Label Promotion Ruling Increases Pressure For FDA Policy Change
Amarin Corp. PLC's First Amendment legal victory on Vascepa (icosapent ethyl) may intensify pressure on FDA to develop new guidance and regulations governing off-label promotion before its hand is further forced by more adverse court rulings and Congress.
FDA Draft Guidance Extends Reprint Policy To Medical Reference Texts, Clinical Practice Guidelines
FDA has revised, but not loosened, its 2009 policy on the practices manufacturers should follow when giving physicians reprints of journal articles and other publications that discuss unapproved uses of legally marketed medical devices and drugs.
Regulatory Briefs: Guidance On Distributing Publications On Unapproved Uses; Export Certification Updates
FDA issues a revised draft guidance on distributing scientific publications on unapproved new uses of medical products. The agency enhances its export certification and tracking system. More regulatory news.